Wir sind mit live! Mehr erfahren

Fresenius Medical Care

FMS

Börsenwert 11,8 Mrd. $

22,17 USD

+0,04

0,18 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

22,20

+0,03

0,14 %

1 Tag

0,18 %

5 Tage

4,38 %

1 Monat

-3,48 %

3 Monate

-7,97 %

6 Monate

-2,64 %

Seit Jahresbeginn

-5,7 %

1 Jahr

-18,01 %

5 Jahre

-36,86 %

10 Jahre

-46,63 %

Profil: Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.

Mitarbeiter: 108.165

Gesundheitswesen Medizinische Versorgungseinrichtungen

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 42,9 %

Neutral 35,7 %

Negativ 21,4 %

Zacks Investment Research

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

Zacks Investment Research

Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth

FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.

Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth

Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership

Refinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expected to result in related one-time costs in Q3 2026 treated as a special item BAD HOMBURG, Germany, Sept. 25, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced refinements to its China commercial strategy to support long-term growth and strengthen its market position through a more localized portfolio, increased commercialization of locally relevant innovation and a focused go-to-market approach.

Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership

Zacks Investment Research

Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?

Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.

Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?

Zacks Investment Research

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

3 Cheap International Stocks to Buy

These stocks have economic moats and look attractive today.

3 Cheap International Stocks to Buy

Zacks Investment Research

FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand

Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript

Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript

Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript

Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights

Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in the second half.

Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights

Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further

Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.

Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt